GleamWall
中文EN

TXMD TherapeuticsMD, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 25743 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY33.9%
TTM net income YoY-59.6%
TTM EPS YoY-50.0%
Revenue 3-yr CAGR24.3%
Net income 3-yr CAGR-87.9%

Margins

Gross margin—
Operating margin-95.3%
Net margin3.3%
FCF margin—
EBITDA margin-85.1%

Returns

ROE0.4%
ROA0.3%
ROIC (approx.)-19.0%
Asset turnover0.10x

Leverage & solvency

Liabilities / assets27.2%
Debt / equity0.00x
Current ratio3.32x
Interest coverage—

Cash quality & payout

Operating cash flow / net income27.59x
Accruals ratio-8.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.26M$869,000$724,000$893,000$784,000$952,000$393,000$667,000
SG&A expense$1.64M$1.58M$1.35M$2.29M$1.52M$1.55M$1.49M-$140,000
Operating income-$479,000-$816,000-$723,000-$1.55M-$862,000-$695,000-$1.28M$700,000
Interest expense———$1,000$3,000$2,000$2,000$1,500
Pretax income$501,000$164,000$103,000-$580,000$50,000$545,000-$668,000$83,000
Income tax————$0$0-$32,000—
Net income$491,000$155,000$95,000-$619,000$152,000$551,000-$653,000$252,000
EBITDA-$382,000-$721,000-$629,000-$1.46M-$766,000-$599,000-$1.19M$800,000
EPS (basic)0.040.010.01—0.010.05-0.06—
EPS (diluted)0.040.010.01—0.010.05-0.06—
Weighted avg. shares (diluted)11.64M11.64M11,640—11.57M11.57M11,552—
Balance sheet
Cash & equivalents$10.45M$9.19M$8.42M$7.48M$7.12M$6.07M$5.75M$5.06M
Current assets$17.42M$16.12M$15.26M$14.45M$14.50M$13.46M$12.51M$12.26M
Intangibles$3.46M$3.56M$3.67M$3.76M$3.91M$4.04M$4.14M$4.32M
Total assets$37.93M$37.53M$37.58M$37.66M$38.67M$38.50M$38.24M$38.82M
Current liabilities$5.25M$5.00M$4.91M$4.79M$4.95M$4.66M$4.74M$5.17M
Total liabilities$10.31M$10.40M$10.61M$10.78M$11.23M$11.21M$11.50M$11.45M
Shareholders' equity$27.62M$27.13M$26.97M$26.88M$27.44M$27.29M$26.74M$27.37M
Shares outstanding11.57M11.57M11.57M11.57M11.57M11.57M11.57M11.53M
Cash flow statement
Operating cash flow$1.27M$779,000$944,000$375,000$999,000$381,000$699,000$17,000
Depreciation & amortization$97,000$95,000$94,000$97,000$96,000$96,000$95,000$100,000
Stock-based compensation$1,000$4,000$2,000$51,000$0$1,000$23,000$24,000

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.